agle-8k_20190430.htm

AEGLEA BIOTHERAPEUTICS, INC.

Date: May 3, 2019

/s/ Charles N. York II

Charles N. York II

Chief Financial Officer

0001564590-19-015734.txt : 20190503 0001564590-19-015734.hdr.sgml : 20190503 20190503170552 ACCESSION NUMBER: 0001564590-19-015734 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190430 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20190503 DATE AS OF CHANGE: 20190503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeglea BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 19797129 BUSINESS ADDRESS: STREET 1: 901 S. MOPAC EXPRESSWAY, STE. 250 STREET 2: BARTON OAKS PLAZA ONE CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: (512) 942-2935 MAIL ADDRESS: STREET 1: 901 S. MOPAC EXPRESSWAY, STE. 250 STREET 2: BARTON OAKS PLAZA ONE CITY: AUSTIN STATE: TX ZIP: 78746 8-K 1 agle-8k_20190430.htm 8-K agle-8k_20190430.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2019

AEGLEA BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37722

46-4312787

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

901 S. MoPac Expressway

Barton Oaks Plaza One

Suite 250

Austin, TX

78746

(Address of principal executive offices)

(Zip Code)

(512) 942-2935

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 Par Value Per Share

AGLE

The Nasdaq Stock Market LLC

(Nasdaq Global Market)

Item 1.01 Entry into a Material Definitive Agreement.

On April 30, 2019, Aeglea BioTherapeutics, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with Las Cimas Owner LP (the “Landlord”), with a commencement date of April 30, 2019. The Lease premises include approximately 30,000 square feet, located at 805 Las Cimas Parkway, Austin, Texas 78746 (the “Premises”). The Company expects to use the Premises as its new corporate headquarters and for laboratory space. The Lease will expire on April 30, 2028, with a Company option to extend the term of the Lease by an additional five-year term. The aggregate estimated rent payments due over the initial term of the Lease is approximately $10.7 million.

The Company will post a customary letter of credit in the amount of $1.5 million as security, which is subject to an automatic reduction per the terms of the Lease. The Landlord also provided the Company with a construction allowance of approximately $1.0 million.

The foregoing description of the Lease is qualified in its entirety by reference to the Lease, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant.

The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease is incorporated into this Item 2.03 by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.